In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy
Source abstract
Abstract
The efficacy of in situ cancer vaccination has been hampered by a poor spatiotemporal orchestration of multiple key steps of the cancer-immunity cycle in most tumours and systemic toxicity related to therapeutic strategies. Here we report a systemic injectable and pyroptosis-enabled nanoadjuvant that evokes the secretion of a vaccine-like pyroptosome in the tumour area for robust antitumour immunity. This systemic injectable and pyroptosis-enabled nanoadjuvant induces vigorous immunogenic pyroptosis, triggering the efficient release of tumour antigen-rich pyroptosomes, damage-associated molecular patterns and proinflammatory cytokines. Photoactivatable release of a TLR7/8 agonist into the pyroptosome generates an in situ cancer vaccine platform that cooperatively activates the cancer-immunity cycle and avoids systemic toxicity. The vaccine boosts both innate and adaptive immune responses, facilitating the eradication of primary tumours and metastatic nodules, thereby providing long-lasting cancer prevention. Overall, the rational design of pyroptosis-inducing nanomedicines for boosting the cancer-immunity cycle reported here might aid in the development of more efficient personalized cancer immunotherapy approaches.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inflammasome and immune disorders · interferon and immune responses · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).10.1038/nature10673 ↗
2. Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).10.1038/s41586-018-0792-9 ↗
3. Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).10.1038/s43018-022-00418-6 ↗
4. Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619–1629 (2022).10.1038/s41591-022-01937-6 ↗
5. Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).10.1038/nature23003 ↗
6. Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355–1360 (2018).10.1126/science.aar7112 ↗
7. Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).10.1038/s41571-020-00460-2 ↗
8. Gong, N. Q. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607–625 (2024).10.1038/s41573-024-00974-9 ↗
9. Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298–312 (2021).10.1038/s41568-021-00339-z ↗
10. Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).10.1126/scitranslmed.abc2816 ↗
11. Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043–1052 (2020).10.1038/s41565-020-00781-4 ↗
12. Wang, C. et al. Oncolytic mineralized bacteria as potent locally administered immunotherapeutics. Nat. Biomed. Eng. 8, 561–578 (2024).10.1038/s41551-024-01191-w ↗
13. Zhang, Y. B. et al. Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy. Nat. Nanotechnol. 18, 1364–1374 (2023).10.1038/s41565-023-01453-9 ↗
14. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).10.1038/nri.2016.107 ↗
15. Aaes, T. L. & Vandenabeele, P. The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death Differ. 28, 843–860 (2021).10.1038/s41418-020-00658-y ↗
16. Bedoui, S., Herold, M. J. & Strasser, A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat. Rev. Mol. Cell Biol. 21, 678–695 (2020).10.1038/s41580-020-0270-8 ↗
17. Meier, P. et al. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat. Rev. Cancer 24, 299–315 (2024).10.1038/s41568-024-00674-x ↗
18. Chen, B. et al. A pyroptosis nanotuner for cancer therapy. Nat. Nanotechnol. 17, 788–798 (2022).10.1038/s41565-022-01125-0 ↗
19. Chen, B., Zhang, Q., Gao, J. & Wang, Y. Control cell death by endosomal trafficking of proton transistor nanophotosensitizers. Life Med. 1, 264–266 (2022).10.1093/lifemedi/lnac023 ↗
20. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543–557 (2009).10.1038/nmat2442 ↗
21. Zhao, R. et al. A pH-responsive nanoparticle library with precise pH tunability by co-polymerization with non-ionizable monomers. Angew. Chem. Int. Ed. 61, e202200152 (2022).10.1002/anie.202200152 ↗
22. Wang, Y. et al. Digitization of endocytic pH by hybrid ultra-pH-sensitive nanoprobes at single-organelle resolution. Adv. Mater. 29, 1603794 (2017).10.1002/adma.201603794 ↗
23. Wang, Z. et al. pH-amplified CRET nanoparticles for in vivo imaging of tumor metastatic lymph nodes. Angew. Chem. Int. Ed. 60, 14512–14520 (2021).10.1002/anie.202102044 ↗
24. Tang, M. et al. pH-gated nanoparticles selectively regulate lysosomal function of tumour-associated macrophages for cancer immunotherapy. Nat. Commun. 14, 5888 (2023).10.1038/s41467-023-41592-0 ↗
25. Akishiba, M. et al. Cytosolic antibody delivery by lipid-sensitive endosomolytic peptide. Nat. Chem. 9, 751–761 (2017).10.1038/nchem.2779 ↗
26. Teo, W. et al. Nile Red fluorescence spectroscopy reports early physicochemical changes in myelin with high sensitivity. Proc. Natl Acad. Sci. USA 118, e2016897118 (2021).10.1073/pnas.2016897118 ↗
27. Fuchs, Y. & Steller, H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat. Rev. Mol. Cell Biol. 16, 329–344 (2015).10.1038/nrm3999 ↗
28. Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).10.1038/s41565-023-01404-4 ↗
29. Adamik, J. & Butterfield, L. H. What’s next for cancer vaccines. Sci. Transl. Med. 14, eabo4632 (2022).10.1126/scitranslmed.abo4632 ↗
30. Guo, Y. et al. In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses. Nat. Commun. 13, 6534 (2022).10.1038/s41467-022-33831-7 ↗
31. Chao, Y. et al. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses. Nat. Biomed. Eng. 2, 611–621 (2018).10.1038/s41551-018-0262-6 ↗
32. Li, W. et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 10, 3349 (2019).10.1038/s41467-019-11269-8 ↗
33. Shekarian, T. et al. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Sci. Transl. Med. 11, eaat5025 (2019).10.1126/scitranslmed.aat5025 ↗
34. Xia, H. et al. A pH-/enzyme-responsive nanoparticle selectively targets endosomal toll-like receptors to potentiate robust cancer vaccination. Nano Lett. 22, 2978–2987 (2022).10.1021/acs.nanolett.2c00185 ↗